Jessica L. Littau
Hamburg, HH, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer's Disease.
Journal: The New England journal of medicine
Published: June 20, 2024
Cleavage site-directed antibodies reveal the prion protein in humans is shed by ADAM10 at Y226 and associates with misfolded protein deposits in neurodegenerative diseases.
Journal: Acta neuropathologica
Published: April 24, 2024
Single-nucleus RNA sequencing demonstrates an autosomal dominant Alzheimer's disease profile and possible mechanisms of disease protection.
Journal: Neuron
Published: May 16, 2023
Resilience to autosomal dominant Alzheimer's disease in a Reelin-COLBOS heterozygous man.
Journal: Nature medicine
Published: October 18, 2022
Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer's dementia.
Journal: Acta neuropathologica
Published: March 29, 2022
Gliovascular alterations in sporadic and familial Alzheimer's disease: APOE3 Christchurch homozygote glioprotection.
Journal: Brain pathology (Zurich, Switzerland)
Published: January 21, 2022
Evidence of beta amyloid independent small vessel disease in familial Alzheimer's disease.
Journal: Brain pathology (Zurich, Switzerland)
Published: August 13, 2021
The blood-brain barrier is dysregulated in COVID-19 and serves as a CNS entry route for SARS-CoV-2.
Journal: Stem cell reports
Published: July 12, 2021
Showing 1-8 of 8
Last Updated: 09/26/2026